The BRCA1 c. 5096G > A p.Arg1699Gln (R1699Q) intermediate risk variant : breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium by Moghadasi, Setareh et al.
15Moghadasi S, et al. J Med Genet 2018;55:15–20. doi:10.1136/jmedgenet-2017-104560
Short report
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) 
intermediate risk variant: breast and ovarian cancer 
risk estimation and recommendations for clinical 
management from the ENIGMA consortium
Setareh Moghadasi,1 huong D Meeks,2 Maaike pG Vreeswijk,3 Linda AM Janssen,1 
Åke Borg,4 hans ehrencrona,5,6 Ylva paulsson-Karlsson,7 Barbara Wappenschmidt,8,9,10 
Christoph engel,11,12 Andrea Gehrig,13,14,15 Norbert Arnold,16 
thomas Van overeem hansen,17,18 Mads thomassen,19 Uffe Birk Jensen,20 
torben A Kruse,19 Bent ejlertsen,18,21 Anne-Marie Gerdes,18,22 
Inge Søkilde pedersen,23,24 Sandrine M Caputo,25 Fergus Couch,26 emily J hallberg,27 
Ans MW van den ouweland,28 Margriet J Collée,28 erik teugels,29 Muriel A Adank,30 
rob B van der Luijt,31,32 Arjen r Mensenkamp,33 Jan C oosterwijk,34 Marinus J Blok,35 
Nicolas Janin,36 Kathleen BM Claes,37 Kathy tucker,38 Valeria Viassolo,39,40 
Amanda ewart toland,41 Diana e eccles,42 peter Devilee,3 Christie J Van Asperen,1 
Amanda B Spurdle,43 David e Goldgar,44 encarna Gómez García35
Cancer genetics
To cite: Moghadasi S, 
Meeks hD, Vreeswijk MpG, 
et al. J Med Genet 
2018;55:15–20.
 ► Additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
jmedgenet- 2017- 104560).
For numbered affiliations see 
end of article.
Correspondence to
Dr encarna Gómez García, 
Department of Clinical Genetics 
Maastricht University Medical 
Centre, Maastricht 6202 AZ, 
the Netherlands;  encarna. 
gomezgarcia@ mumc. nl
SM and hDM contributed 
equally.
received 24 January 2017
revised 11 April 2017
Accepted 17 April 2017
published online First 
10 May 2017
AbsTrACT
background We previously showed that the BRCA1 
variant c.5096G>A p.Arg1699Gln (r1699Q) was 
associated with an intermediate risk of breast cancer 
(BC) and ovarian cancer (oC). this study aimed to assess 
these cancer risks for r1699Q carriers in a larger cohort, 
including follow-up of previously studied families, to 
further define cancer risks and to propose adjusted 
clinical management of female BRCA1*r1699Q carriers.
Methods Data were collected from 129 
BRCA1*r1699Q families ascertained internationally by 
eNIGMA (evidence-based Network for the Interpretation 
of Germline Mutant Alleles) consortium members. A 
modified segregation analysis was used to calculate BC 
and oC risks. relative risks were calculated under both 
monogenic model and major gene plus polygenic model 
assumptions.
results In this cohort the cumulative risk of BC and 
oC by age 70 years was 20% and 6%, respectively. the 
relative risk for developing cancer was higher when using 
a model that included the effects of both the r1699Q 
variant and a residual polygenic component compared 
with monogenic model (for BC 3.67 vs 2.83, and for oC 
6.41 vs 5.83).
Conclusion our results confirm that BRCA1*r1699Q 
confers an intermediate risk for BC and oC. Breast 
surveillance for female carriers based on mammogram 
annually from age 40 is advised. Bilateral salpingo-
oophorectomy should be considered based on family 
history.
InTroduCTIon
In 2008, the International Agency for Research on 
Cancer (IARC) proposed a standardised five-tier 
classification system applicable to sequence-based 
results in highly penetrant cancer predisposition 
genes and linked the likelihood of pathogenicity 
to clinical actions.1 The multifactorial likelihood 
model (MLM) is commonly used to calculate the 
probability of pathogenicity2 of individual BRCA1 
and BRCA2 variants. It is used in the IARC five-tier 
classification system to categorise each variant into 
a specific class. The MLM combines complemen-
tary sources of data (ie, physicochemical proper-
ties,3 family history,4 cosegregation of the variant 
with disease in a family5 and co-occurrence of the 
variant with a pathogenic BRCA1 or BRCA2 variant 
in trans6) to determine the probability that a given 
variant has a cancer risk equivalent to known 
high-risk pathogenic (predominantly truncating) 
variants.
The BRCA1 variant c.5096G>A p.Arg1699Gln 
(hereafter termed BRCA1*R1699Q) was initially 
classified as class 3 (variant of uncertain signif-
icance) using the MLM method.1 A subsequent 
study7 included functional assays to assess patho-
genicity, but did not yield conclusive results. 
Indeed this variant, located in the BRCA1 carboxyl 
terminal region of the transcriptional transactiva-
tion domain, and at the interface of the phospho-
peptide binding region, demonstrated ambiguous 
behaviour in a variety of functional assays, when 
compared with the pathogenic BRCA1 variant 
c.5095C>T p.Arg1699Trp (BRCA1*R1699W) 
at the same residue, wild-type BRCA1 and other 
known pathogenic missense variants.7 Other 
models based on family history analysis of BRCA-
ness8 or cosegregation within a family5 also gave 
inconclusive results.
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In 2012, members of the ENIGMA consortium (Evidence-
based Network for the Interpretation of Germline Mutant 
Alleles)9 reported on the family histories of 69 families carrying 
BRCA1*R1699Q.10 Comparison of BRCA1 carrier prediction 
scores of probands using the BOADICEA risk prediction tool11 
showed that BRCA1*R1699Q variant carriers had family histo-
ries that were less ‘BRCA1-like’ than BRCA1*R1699W carriers 
but more ‘BRCA1-like’ than BRCA-X families (families with 
no detectable BRCA1 or BRCA2 pathogenic mutation). Second, 
modified segregation analysis was used in a subset of 30 fami-
lies and showed lower risks of breast cancer (BC) or ovarian 
cancer (OC) (estimated cumulative risk to age 70: 24%) than 
BRCA1*R1699W (58%) and the ‘average’ pathogenic BRCA1 
truncating variant (68%).10 Due to the relatively small number of 
families with cosegregation data in that study, age-specific cancer 
risks could not be established with a high degree of precision.
The aim of the present study was to update the BC and OC 
risk estimates associated with BRCA1*R1699Q in a larger series 
that included newly identified families, as well as some of the 
previously studied families, which had been updated with coseg-
regation data as a result of cascade screening. Based on these 
results, we propose recommendations for the clinical manage-
ment of the carriers and their family members.
MATerIAls And MeThods
data collection
All families participating in this study included one or more indi-
viduals referred to a cancer family clinic because of a personal 
history of BC and/or OC, and/or a family history consistent with 
hereditary BC and/or OC.
Each index case had a confirmed BRCA1*R1699Q variant. 
ENIGMA members, including those from centres that had 
contributed pedigrees to the previous study, were asked to 
provide updated pedigrees (if possible) and additional families 
segregating BRCA1*R1699Q identified after the close of enrol-
ment of the previous study. Pedigrees and patient-specific data 
such as ages at diagnoses and genotypes were collected from a 
total of 129 families from 11 different countries, of which 91 
families had at least one additional person genotyped, and were 
thus informative for estimating BC and OC risks. From these 91 
families, 30 had been included in the segregation analysis in our 
previous study10 (see online supplementary table S1). When ages 
of diagnosis were missing, we conservatively assumed them to be 
age 65, and for unaffected women we imputed their age using 
other pedigree members using the PedPro suite of programs 
(www. bjfenglab. org, accessed 21 September 2016).
statistical analysis
Data sets
In order to account for ascertainment bias, the likelihood of 
the pedigree phenotypes and BRCA1*R1699Q genotypes was 
calculated conditional on the pedigree phenotypes and the 
BRCA1*R1699Q genotype of the index case. Cancer risks were 
estimated using the following data sets:
The primary analysis (hereafter termed main analysis) included 
all 129 informative pedigrees from both the previous study and 
the present recruitment. The second analysis (subanalysis 1) was 
similar to the main analysis, except that for the genotypes and 
phenotypes from the previous study only information gathered 
since the previous study is included. In this analysis, the likeli-
hood was conditioned on the genotype of the index case and 
pedigree phenotypes of the new families and all genotypes and 
pedigree phenotypes in the previous pedigrees as they were in 
the previous analysis in 2012. In fact the index patients carrier 
status and affected status are not used to estimate the hazard/
risk ratios on which the cumulative risks are based. The last 
analysis (subanalysis 2) included only the 60 pedigrees that were 
recruited for this study.
Data from subanalyses 1 and 2 are shown in the online supple-
mentary materilas.
Cancer risk estimation methods
BC and OC risks were estimated using modified segregation 
analysis with the MENDEL package of programs.12 For each 
data set, the analysis was performed under each of the following 
assumptions:  (1) the relative risk (RR) across age groups was 
assumed to be constant; and (2) the RR was assumed to be a 
continuous, piecewise linear function of age, which was constant 
before age 40 years and after age 60 years and linear between 
ages 40 and 60 years. For both models, baseline population inci-
dence rates were assumed to be those for the UK 2003–2007 
(Cancer Incidence in Five Continents Reports (IARC-WHO; 
update November 2010).13
For both these analyses we first used a model assuming a single 
major gene only (the BRCA1*R1699Q variant) and second a 
model that included the major gene and a polygenic background 
effect. From the resulting estimates of BC and OC relative risk, 
age-specific cumulative risk estimates were calculated based on 
the cumulative incidence Λ(t): F(t)=1 − exp(−Λ(t)), and the 
corresponding CIs were calculated using a parametric bootstrap 
with 5000 replications.14
resulTs
descriptive characteristics of the cohort
Our cohort included 129 separate families with a total of 
4024 family members, from whom 309 women were proven 
BRCA1*R1699Q carriers and 173 were proven non-carriers. For 
91 families, in addition to genotyping data of the proband, at 
least one additional genotype was available (see online supple-
mentary table S2). Descriptive characteristics of the cohort about 
BC and OC cancer history and age distribution are listed in the 
online supplementary table S2.
bC and oC risks
Online supplementary figure S1 and supplementary table S2 
show the age distribution for BC and OC for the female carriers. 
The sharpest increase of BC occurred between ages 40 and 49. 
For OC this was between ages 50 and 59. The youngest case of 
BC was diagnosed at age 25, for OC this was age 35.
Cumulative risks for this variant by age 70 years are estimated 
to be 20% (95% CI 13% to 32%) for BC and 6% (95% CI 3% 
to 25%) for OC. The risks are lower than for high-risk BRCA1 
truncating variants and higher than for the general population in 
all the three data sets. Figure 1 shows the corresponding curves 
for the main analysis. Online supplementary figures S2 and S3 
and supplementary tables S3 and S4 show comparable results for 
all the data sets under both assumptions.
effect of other genetic factors on cancer risks
In order to study the effect of other (genetic) factors on risk, 
HRs were calculated based on the ‘major gene only’ model and 
the ‘major gene and polygenic’ model under both assumptions.
For the main analysis, HRs for BC are higher in the major 
gene plus polygenic model compared with the major gene only 
model, both when assuming constant RR across age groups, and 
when modelled as a continuous piecewise linear function of age. 
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HRs for OC are higher in the major gene plus polygenic model 
when assuming constant RR. When assuming RR as a contin-
uous, piecewise linear function of age, the HR is higher for the 
major gene plus polygenic model when the individual is older 
than 60 years old, suggesting that modifiers might be especially 
important for the late-onset disease (table 1). Online supple-
mentary table S5 shows the HRs for the subanalyses.
dIsCussIon
After publication of the study by Spurdle et al10 in 2012, many 
cancer clinics started offering cascade screening to relatives of 
carriers of the BRCA1*R1699Q variant. However, in the absence 
of robust estimates of cancer risks, it was not clear whether 
available guidelines for BRCA carriers would also be suitable for 
female carriers of BRCA1*R1699Q.
The cumulative risks estimated from the main analysis and the 
two subanalyses were lower than for the average BRCA1 trun-
cating pathogenic variant, yet still substantially higher than the 
rates in the general population. Cumulative risk by age 70 years 
was estimated to be 20% (95% CI 13% to 32%) for BC and 6% 
(95% CI 3% to 25%) for OC.
Our results strongly confirm our previous findings that this 
variant has reduced penetrance,10 and can thus be termed an 
intermediate risk variant conferring risks lower than that for the 
average pathogenic variant in a high-risk cancer predisposition 
gene. These risk estimates are consistent with those reported for 
disease-associated variants in so-called ‘moderate risk’ genes, 
defined as genes in which pathogenic variants have an RR 
between 2 and 5.15 16
Interestingly, our results show that the estimated HRs are in 
general slightly higher when the ‘major gene plus polygenic’ 
model is used compared with the ‘major gene only’ model, 
which is especially evident in the late-onset disease (>60 years) 
group. This means that in addition to BRCA1*R1699Q, other 
genetic and/or environmental factors seem to contribute to the 
magnitude of the BC and OC risk in carriers. Indeed, recent 
literature15–17 indicates that single nucleotide polymorphisms 
are important determinants of personal cancer risk in women 
carrying a deleterious disease-associated variant especially in 
moderate risk genes. As those factors are mostly unmeasured 
or unknown, an indirect estimation of clustering of risk factors 
can be deduced taking the family history into account. This is 
particularly relevant to consider when deciding surveillance for 
healthy relatives who are non-carriers of deleterious variants 
in the moderate risk genes, or non-carriers of intermediate risk 
variants in ‘high-risk cancer predisposition genes’ such as BRCA1 
or BRCA2.
The relevance of these findings for clinical management of 
BRCA1*R1699Q carriers and their relatives was considered during 
the Clinical Working Group meeting at the April 2016 ENIGMA 
conference, held in Prague, which was attended by 38 members 
with expertise in laboratory research, statistics and clinical 
genetics. Recommendations for CHEK2 c.1100delC carriers17 18 
and country-specific guidelines including Oncoline (The Neth-
erlands: http://www. oncoline. nl, accessed 21 September 2016), 
National Institute for Health and Care Excellence (UK: https://
www. nice. org. uk, accessed 21 September 2016) and National 
Comprehensive Cancer Network (USA: https://www. nccn. org, 
accessed 21 September 2016) were used as a framework to guide 
discussion. A consensus and majority-based discussion led to the 
following opinions and recommendations:
Female non-carriers of BRCA1*r1699Q from BRCA1*r1699Q 
families
Surveillance should depend on (family) history of cancer, for 
example, on the risk calculated using programs like BOADICEA.11
Female carriers of BRCA1*r1699Q
A cumulative risk of BC (20% (95% CI 13% to 32%)) does not 
by itself justify preventive mastectomy or breast MRI. Breast 
Figure 1 Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*r1699Q based on the 
main analysis (blue line). the corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general 
population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming relative risk as a continuous, 
piecewise linear function of age.
Table 1 Modified segregation analysis results from MENDEL in the 
main analysis (a) assuming constant relative risk across age groups 
and (b) assuming relative risk as a continuous, piecewise linear 
function of age
Model hr (a) Age hr (b)
Breast Major gene only 2.83 (1.76, 4.57) <40 4.72 (2.22, 10.02)
>60 1.75 (0.75, 4.05)
Major and polygenic 3.67 (1.97, 6.81) <40 5.05 (2.07, 12.34)
>60 2.71 (1.09, 6.75)
Ovarian Major gene only 5.83 (2.19, 15.49) <40 5.91 (0.58, 60.20)
>60 5.81 (1.80, 18.76)
Major and polygenic 6.41 (2.19, 18.75) <40 5.39 (0.48, 61.10)
>60 6.75 (1.96, 23.22)
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surveillance for female carriers based on annual mammogram 
from age 40 up to 50 years and inclusion in population screening 
afterwards is advised.
Combining with family history, the BC risk might be estimated 
to be higher than the risk conferred by the variant alone. If this 
is the case, the surveillance advice for BRCA1*R1699Q carriers 
can be ‘overruled’ by the higher family history risk and addi-
tional genetic testing can be considered.
The specific genes included will vary across countries depen-
dent on testing practices, which incorporate availability and 
extent of panel-based testing, eligibility for health insurance 
or state-based testing, clinical guidelines for ascertainment 
including number and types of cancer reported in families, etc 
(ENIGMA, unpublished findings). Genetic testing for variants 
in other genes using a panel approach for a range of BC/OC 
susceptibility genes may offer some additional genotype-based 
information about risk in those cases; however, penetrance esti-
mates for the majority of other genes beyond BRCA1, BRCA2 
and PALB2 are imprecise.16 Furthermore, it is still unclear how 
genetic risks are best combined to produce more accurate, indi-
vidualised, risk estimates.
The BRCA1*R1699Q variant carriers have lower OC risk (6% 
(95% CI 3% to 25%)), compared with that for BRCA1 carriers 
(39% (95% CI 22% to 51%)) and BRCA2 carriers (11% (95% 
CI 4.1% to 18%)).19 Bilateral salpingo-oophorectomy (BSO) is 
the standard preventive treatment in the Netherlands for high-
risk pathogenic variant carriers, performed at age 35–40 for 
BRCA1 and 40–45 for BRCA2 (http://www. oncoline. nl). Routine 
surveillance for OC is not effective and is no longer offered 
to carriers.20 The magnitude of OC risk for R1699Q carriers 
suggests that BSO, if performed, may be postponed until age 50. 
We advise BSO surgery should be offered at age 50, based on 
the age-related cumulative risks for OC obtained from the study. 
The cumulative lifetime risk of OC for someone in the general 
population is approximately 1.5%, but the vast majority of risk 
occurs after 50 years of age. From our study the cumulative OC 
risk for BRCA1*R1699Q carriers by age 50 is lower than the 
cumulative population risk for OC and rises significantly after 
age 55. Although BSO surgery could be offered at any age after 
the genetic risk is identified, we base our guidance on a prag-
matic balance between cancer prevention and minimum adverse 
effects from early oestrogen deprivation, achieved if the surgery 
is timed around the current average age for the menopause in 
the Western society (52 years).
However, as for BC risk management, and considering 
the wide CI for the estimated risk of OC, information about 
cancer history in the family should be taken into account for 
decision making.
ConClusIon
Our analysis of a large cohort of 129 families, using several 
analytical approaches, confirms that the BRCA1*R1699Q 
variant is associated with intermediate cancer risks (compared 
with the average BRCA1 truncating variant). It also provides 
evidence that cancer risk in carriers is likely to be influenced by 
other genetic factors. Based on our findings, we propose recom-
mendations for the clinical management of BRCA1*R1699Q 
carriers and non-carriers. We recommend that follow-up and 
screening in these families are performed in a research setting in 
order to enable future assessment of the utility of the proposed 
surveillance.
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